stockrow
Friday 6 November 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024.
- Revenue
- +21.5%
- EPS
- +25.0%
- Free cash flow
- +40.9%
- Total debt
- +1.48%
Quarter to September 2026, against a year earlier
7.76
0.12
−1.52%
Follow TKNO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.02 | 3.71 | 6.97 | 10.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(439.90) | (46.12) | (646.81) | (373.93) | |
P/B ratio |
2.96 | 2.39 | 4.87 | 7.99 | |
Price to Tangible BV |
3.58 | 2.91 | 5.95 | 9.81 | |
EV/Sales |
4.91 | 3.69 | 6.97 | 10.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(23.02) | (19.53) | (48.54) | (85.93) | |
EV/FCF |
(20.33) | (17.03) | (41.41) | (74.97) | |
Quick Ratio |
3.44 | 3.40 | 3.32 | 2.51 | |
Current Ratio |
4.58 | 4.59 | 4.49 | 3.56 | |
Net Debt/EBITDA |
2.69 | 1.65 | 3.31 | 0.00 | |
Debt/Assets |
12.67% | 13.35% | 13.79% | 14.01% | |
Debt/Equity |
0.19 | 0.20 | 0.21 | 0.22 | |
Asset Turnover |
0.36 | 0.39 | 0.42 | 0.45 | |
Operating CF/Net income |
0.10 | 0.74 | 0.15 | 0.37 | |
Capex/Depreciation |
(0.22) | (0.15) | (0.08) | 0.00 | |
Interest Coverage |
(21.84) | (19.63) | (11.47) | (12.38) | |
Research and Development Expense of Revenue |
5.23% | 5.50% | 4.55% | 4.57% | |
Selling, General and Administrative Expense of Revenue |
70.55% | 64.87% | 56.91% | 56.39% | |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
7.78% | 6.27% | 5.10% | 4.82% | |
Graham Net Nets |
0.00 | (0.01) | (0.01) | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.68%) | (11.07%) | (5.46%) | (3.26%) | |
Free Cash Flow Yield |
(4.82%) | (5.85%) | (2.41%) | (1.34%) | |
Revenue per Share |
0.19 | 0.21 | 0.23 | 0.24 | |
Operating CF per Share |
(0.01) | (0.06) | (0.01) | (0.02) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.07) | (0.01) | (0.03) | |
Cash per Share |
0.40 | 0.33 | 0.33 | 0.31 | |
Shareholders Equity per Share |
1.29 | 1.21 | 1.17 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.29 | 1.21 | 1.17 | 1.11 | |
Free Cash Flow |
(0.81) | (3.58) | (0.60) | (1.40) | |
Working Capital |
26.97 | 24.78 | 23.95 | 22.87 | |
Capital Expenditures |
(0.35) | (0.22) | (0.12) | (0.12) | |
Net Current Asset Value |
(0.30) | (2.06) | (2.45) | (3.10) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.47 | 5.64 | 5.27 | 5.48 | |
Average Payables |
1.10 | 1.59 | 1.32 | 1.45 | |
Average Inventory |
6.93 | 6.72 | 7.26 | 7.20 | |
Average Assets |
111.18 | 106.33 | 103.18 | 101.15 | |
Average Common Equity |
75.58 | 71.76 | 69.33 | 66.22 |
Columns are period end dates · fundamentals updated 5 Nov 2026